Evidence map›Paper›PMID 42053472›Full record

ArticleJournal of the American College of Cardiology2026

Development and Validation of a Clinical Polygenic Risk Report in U.S.-Based Health Systems for 8 Cardiovascular Conditions.

Anika Misra, Amanda Jowell, Sara Haidermota, Emma Perez, Lisa Mahanta, Kimberly J O'Brien, Anna Nagy, Limin Hao, Buu Truong, Krishna Aragam and 10 more

Abstract readValidation Study
In one paragraph

Article in Journal of the American College of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Genetic Causes of Thoracic Aortic Aneurysm: A Review.Methodist DeBakey cardiovascular journal · 2026
    Review
  5. Polygenic risk score translation across diverse populations.Frontiers in cardiovascular medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anika MisraProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Amanda JowellProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Mass General Brigham Department of Medicine, Boston, Massachusetts, USA.
Sara HaidermotaProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Emma PerezMass General Brigham Department of Medicine, Boston, Massachusetts, USA; Mass General Brigham Personalized Medicine, Boston, Massachusetts, USA.
Lisa MahantaMass General Brigham Personalized Medicine, Boston, Massachusetts, USA.
Kimberly J O'BrienMass General Brigham Personalized Medicine, Boston, Massachusetts, USA.
Anna NagyMass General Brigham Personalized Medicine, Boston, Massachusetts, USA.
Limin HaoMass General Brigham Personalized Medicine, Boston, Massachusetts, USA.
Buu TruongProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Krishna AragamProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Akl C FahedProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Mass General Brigham Heart and Vascular Institute, Boston, Massachusetts, USA.
Shaan KhurshidProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Mass General Brigham Heart and Vascular Institute, Boston, Massachusetts, USA; Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, Massachusetts, USA.
Patrick T EllinorProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Mass General Brigham Heart and Vascular Institute, Boston, Massachusetts, USA; Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, Massachusetts, USA.
Anna C F LewisProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Genetics, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Niall LennonGenomic Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Whitney HornsbyProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Matthew S LeboProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Mass General Brigham Personalized Medicine, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Elizabeth W KarlsonMass General Brigham Department of Medicine, Boston, Massachusetts, USA; Mass General Brigham Personalized Medicine, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Pradeep NatarajanProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Mass General Brigham Heart and Vascular Institute, Boston, Massachusetts, USA. Electronic address: pnatarajan@mgh.harvard.edu.
Aniruddh P PatelProgram in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Mass General Brigham Heart and Vascular Institute, Boston, Massachusetts, USA. Electronic address: apatel32@mgh.harvard.edu.

Funding

Polygenic Risk Score Methods Development Consortium Coordinating CenterU01HG011697 · NHGRI · UNIVERSITY OF WASHINGTON · PI Kenneth M. Rice · 2021 to 2026
$8.8M
Using genetic variation to study biology of blood lipids & coronary heart diseaseR01HL127564 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Pradeep Natarajan, Gina Marie Peloso · 2015 to 2026
$7.3M
Enabling improved applicability and transferability of polygenic scores across populationsU01HG011719 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI Alicia Martin · 2021 to 2026
$5.5M
Electrocardiogram-based deep learning and decision analysis to improve atrial fibrillation risk estimationK23HL169839 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Shaan Khurshid · 2023 to 2026
$860k
Advancing the clinical actionability of polygenic scores for coronary artery diseaseK08HL168238 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Aniruddh Patel · 2024 to 2026
$511k
NHGRI NIH HHS U01 HG011697NHGRI NIH HHS U01 HG011719NHLBI NIH HHS K08 HL168238NHLBI NIH HHS K23 HL169839NHLBI NIH HHS R01 HL127564
6 · The paper itself

Abstract

backgroundPolygenic risk scores (PRS) stratify inherited cardiovascular risk, but their path to clinical implementation remains unclear.

objectivesWe aimed to develop and validate integrated PRS for 8 cardiovascular conditions and outline a framework for their clinical reporting.

methodsWe analyzed genotype and clinical data from 245,394 All of Us Research Program participants. Publicly available PRS for 8 traits-coronary artery disease, atrial fibrillation, type 2 diabetes, venous thromboembolism (VTE), thoracic aortic aneurysm (TAA), extreme hypertension, severe hypercholesterolemia, and elevated lipoprotein(a)-were combined using PRSmix, an elastic-net approach. Integrated PRS were externally validated in 53,306 Mass General Brigham Biobank participants using logistic regression, adjusting for age, sex, and ancestry.

resultsOf 53,306 genotyped Mass General Brigham Biobank participants (55.6% women, mean age 53 ± 17 years), integrated PRS demonstrated robust discrimination and appropriate calibration across 8 cardiovascular traits. Comparing high genetic risk (top 10% of PRS distribution, or top 20% for rarer TAA and VTE) vs average risk (26th-75th percentiles, or 21st-80th percentiles for TAA and VTE) yielded ORs: coronary artery disease (3.7 [95% CI: 3.4-4.1]), type 2 diabetes (3.1 [95% CI: 2.8-3.3]), atrial fibrillation (3.0 [95% CI: 2.7-3.3]), VTE (1.9 [95% CI: 1.6-2.0]), TAA (1.7 [95% CI: 1.5-1.9]), hypertension (2.1 [95% CI: 1.8-2.3]), hypercholesterolemia (4.1 [95% CI: 3.7-4.5]), and lipoprotein(a) (41.0 [95% CI: 27.0-62.2]). Incorporating integrated PRS into clinical models improved risk classification, while prospective analyses confirmed significant associations with incident cardiovascular outcomes.

conclusionsIntegrated PRS offer an implementable framework for genetic risk reporting, and are now available as a clinically orderable test. Broader prospective validation studies are needed to further establish clinical utility.

Indexed as

Cardiovascular DiseasesAdultAgedAortic Aneurysm, ThoracicAtrial FibrillationCoronary Artery DiseaseDiabetes Mellitus, Type 2FemaleGenetic Predisposition to DiseaseGenetic Risk ScoreHumansHypercholesterolemiaHypertensionLipoprotein(a)MaleMiddle AgedLipoprotein(a)biobankgenomicspreventionrisk stratificationscreening

Identifiers

PMID42053472
PMCPMC13380837

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.